Cargando…
Efficacy of 0.01% atropine for myopia control in a randomized, placebo-controlled trial depends on baseline electroretinal response
This study aimed to evaluate the efficacy of 18-month 0.01% atropine in 61 myopic children (aged 7–10) and the relationship with central retinal response (by multifocal electroretinogram [mfERG]) in a double-masked randomized placebo-controlled clinical trial. Global-flash mfERG was measured at base...
Autores principales: | Chan, Henry H. L., Choi, Kai Yip, Ng, Alex L. K., Choy, Bonnie N. K., Chan, Jonathan Cheuk Hung, Chan, Sonia S. H., Li, Serena Z. C., Yu, Wing Yan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9270320/ https://www.ncbi.nlm.nih.gov/pubmed/35804049 http://dx.doi.org/10.1038/s41598-022-15686-6 |
Ejemplares similares
-
Effect of atropine 0.01% on progression of myopia
por: Sen, Snigdha, et al.
Publicado: (2022) -
Use baseline axial length measurements in myopic patients to predict the control of myopia with and without atropine 0.01%
por: Rose, Loreto V. T., et al.
Publicado: (2021) -
Analysis of Factors That May Affect the Effect of Atropine 0.01% on Myopia Control
por: Zhang, Xiaoyu, et al.
Publicado: (2020) -
Effects of atropine 0.01% on refractive errors in children with myopia
por: Zhu, Xingxue, et al.
Publicado: (2023) -
Efficacy and Safety of Consecutive Use of 1% and 0.01% Atropine for Myopia Control in Chinese Children: The Atropine for Children and Adolescent Myopia Progression Study
por: Ye, Luyao, et al.
Publicado: (2022)